*All times listed are Central European Time (CET)
Conference Day 1
Wednesday 6th December 2023
7:00 am Registration
7:50 am Opening Remarks
Evaluating the Current Market & Clinical Updates to Understand the Progress in the Field
8:00 am Advancing Bayer’s (Pre)clinical TRT Pipeline
Synopsis
• Reviewing preclinical assets and modalities
• Diving into combinations
• Exploring the clinical assets
8:30 am Coretag’s Necrosis Targeted Radioligand, the First in Human Use
Synopsis
• Improving biodistribution by adding albumin binding component
• Radiolabeling for Petscan
• Radiolabeling for Therapeutic use
9:00 am Accelerate clinical development for Molecular RadioTherapies (MRT)
Synopsis
- Novel services and technologies in preclinical MRT studies
- Using multiple legislations to optimize clinical trial conduct (EU & USA)
- Capitalization on untapped development capacities for MRT (focus on India)
9:40 am Morning Break & Speed Networking
Novel Targets Track
Moulding Your TRP to Work Around the Challenges Associated With Novel Targets
10:40 am Novel Fibrosis Targets for Molecular Imaging of Fibrogenesis & Fibrotic Cancers
Synopsis
• Explore attractive targets for fibrogenesis
• Discover the use of a single domain antibodies platform for molecular imaging
• Review translation from diagnostic targets to therapeutic targets
11:10 am Roundtable Discussion – Understanding How to Choose the Correct Oncological Target to Adapt Your TRP to Changing Tumor Expressions
Synopsis
- Navigating changing tumour expression
- Reflecting on how this expression affects target selection
- Analysing what makes a good target given changing tumour expression
11:25 am Targeting HER2 & FAP to Address Unmet Need With New Treatment Modality
Synopsis
• Why we have selected HER2 and FAP as our lead targets
• How we stand out from competition
• Sharing accomplishments and future plans
Supply Chain Track
Delving into the Supply Chain & Transportation Challenges Associated With Novel Isotopes
10:40 am An Overview of Zirconium-89: From Production to Clinical Utility
Synopsis
• Evaluating the production and properties of Zr-89
• Reviewing the current and emerging global supply chain of Zr-89
• Discussing the advantages, limitations, and future prospects including clinical utility
11:10 am Company Introduction & Copper 67 API
Synopsis
• Iotron Medical is the only commercial supplier of copper 67
• Discussing beta-emitting therapeutic isotope with Cu-64 for PET Imaging
11:25 am Unlocking Shortage of Alpha Emitting Isotope With Lead-212 to Tap TAT Full Potential
Synopsis
• Interest of lead-212 for the development of TRP
• Providing a reliable supply chain for 212Pb-based therapies
• Developing a robust pipeline of 212Pb-based therapies for patients’ benefit
11:55 am Networking Lunch
Taking a Deep Dive into Novel Targets & Their Basics to Understand How They Affect TRP Development
1:00 pm Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors
Synopsis
• Exploring preclinical & clinical (Phase 1, Phase 2) data
• Applying this to notoriously-difficult to treat recurrent glioblastoma
• How effective is this for treating pediatric ependymoma & high-grade gliomas
1:30 pm Evaluating the targeting and therapeutic efficiency of alpha & beta emitting radiopharmaceuticals, through non-invasive in vivo screening
Synopsis
- Preclinical in vivo imaging, serves as a gold-standard methodology for diagnostic radiopharmaceuticals evaluation
- Imaging of therapeutic isotopes (including a-emitters) is more challenging to establish and export relative data
- The proposed in vivo screening protocol, significantly enriches the study read-outs, during a standard preclinical drug efficacy study
1:45 pm Branching Out: DEP® Dendrimer Nanoparticles as a Versatile Platform for Precision Cancer Radiotheranostics
Synopsis
• Starpharma’s polylysine DEP® dendrimers for development of radiotheranostic pairs
• Utility of DEP® platform for targeted delivery of radiotheranostics
• Overview of DEP® HER2-targeted radiotheranostics
Optimising Manufacturing & Supply Coordination to Accelerate TRP Development
1:00 pm The Modular PreTargit® Platform Enables RIT for Hard-to-Treat Cancers by Significantly Improved Therapeutic Indexes
Synopsis
• PreTargit Radioimmunotherapies
• Analysing antibody design
• Efficacy of PRIT on mouse models of colorectal and pancreatic cancer
1:30 pm Meeting Ambitious Time-To-Market Goals in a Fast-Growing TRP Market
Synopsis
• Our approach to TRP time-to-market efficiency
• Staying on course in a fast-growing environment
• Achievements and future steps in API process development & manufacturing
1:45 pm Improving Turn Around Time of TRP From Manufacturer to Patient to Keep With Set Dosing Schedules
Synopsis
• Learning what turnaround time is and why it is important
• Scrutinising the problem with turnaround times
• Enhancing turnaround times to ensure dosing schedules are not affected
2:15 pm Afternoon Networking Break
3:00 pm Panel Discussion – Understanding the Investor Landscape to Maximise Investments & Drive TRP Development
Synopsis
• Examining the investor landscape
• Understanding how to optimise opportunities in the investor landscape
• Maximising investments in your TRP
Addressing the Advantages of Imaging to Use It as a Companion to Therapy & Improve Diagnostics
4:00 pm Pharmalogic Company Overview
Synopsis
- Therapeutic and PET manufacturing expansion
- Chemistry development and scale – up
- Clinical and commercial supply considerations
4:15 pm Delving into the ImmunoPET Potential for Drug Development
Synopsis
• Explore opportunities and challenges for bioimaging in clinical drug development
• Examine D8-PET as biomarker of response to IO treatments
4:30 pm Closing Remarks
4:45 pm Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings.
5:45 pm End of Scientific Programme Day One
